Literature DB >> 9635844

The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study.

I Brotherick1, D A Browell, B K Shenton, M Egan, W J Cunliffe, L A Webb, L G Lunt, J R Young, M J Higgs.   

Abstract

The effect of 3-week, preoperative tamoxifen treatment on oestrogen receptor (ER) levels, expressed by primary breast tumours, was examined. Patients (age-matched) with breast cancer, confirmed by fine-needle aspiration, were either treated with 20 mg ml(-1) oral tamoxifen per day or received no medication in the 3-week interval between assessment and surgery. Quantification of ER using flow cytometry was performed on the surgically removed tumour samples from tamoxifen-treated (n = 40) and control (n = 38, untreated) patient groups. The tumours were mechanically disaggregated, and saponin treatment rendered these cells permeable to antibodies. Using dual-parameter labelling with a FITC-conjugated antibody (NCL-5D3) directed against cytokeratin 8/18/19 and a biotinylated antibody (DAKO-ER 1D5) directed against the oestrogen receptor, ER quantification was determined on a number of receptors per cell basis. Using QC quantum bead standards, ER levels in the epithelial cell population, the non-epithelial cell population and the whole-cell population (ER+) were calculated. ER levels were significantly lower in the total cell population than tamoxifen-treated patients (P = 0.002) when compared with the control (untreated) group. By using a gating procedure using 5D3 antibody positivity, a significantly lower level was detected on examining the cytokeratin-positive population alone (P = 0.006). Using a complementary gating technique, ER levels were quantified in the cytokeratin-negative cell population. Examination of this group of cells showed no significant difference between the levels of oestrogen receptor found in the tamoxifen-treated and untreated groups (P = 0.4). We have demonstrated that ER levels can be monitored by flow cytometry. ER levels in patients treated with tamoxifen 3 weeks before operation are significantly lower than in a comparative group of patients who received no drug. Furthermore, the most significant difference in receptor levels is seen by quantification of total ER levels expressed by all the tissue.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9635844      PMCID: PMC2150047          DOI: 10.1038/bjc.1998.272

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  16 in total

Review 1.  Steroid receptors: elements for modulation of eukaryotic transcription.

Authors:  K R Yamamoto; B M Alberts
Journal:  Annu Rev Biochem       Date:  1976       Impact factor: 23.643

2.  NCL-5D3: a new monoclonal antibody recognizing low molecular weight cytokeratins effective for immunohistochemistry using fixed paraffin-embedded tissue.

Authors:  B Angus; J Purvis; D Stock; B R Westley; A C Samson; E G Routledge; F H Carpenter; C H Horne
Journal:  J Pathol       Date:  1987-12       Impact factor: 7.996

3.  Image cytometry of estrogen receptors in breast carcinomas.

Authors:  O Cohen; G Brugal; D Seigneurin; J Demongeot
Journal:  Cytometry       Date:  1988-11

4.  Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma.

Authors:  C A Sawka; K I Pritchard; A H Paterson; D J Sutherland; D B Thomson; W E Shelley; R E Myers; B G Mobbs; A Malkin; J W Meakin
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701

5.  Functional domains of the human estrogen receptor.

Authors:  V Kumar; S Green; G Stack; M Berry; J R Jin; P Chambon
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

6.  Oestrogen receptor assay--limitation of the method.

Authors:  H S Poulsen
Journal:  Eur J Cancer       Date:  1981-05       Impact factor: 9.162

7.  Estrogen control of progesterone receptor in human breast cancer: role of estradiol and antiestrogen.

Authors:  K B Horwitz; Y Koseki; W L McGuire
Journal:  Endocrinology       Date:  1978-11       Impact factor: 4.736

8.  Steroid-hormone receptors and survival after first relapse in breast cancer.

Authors:  A Howell; D M Barnes; R N Harland; J Redford; V H Bramwell; M J Wilkinson; R Swindell; D Crowther; R A Sellwood
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

9.  Effects of tamoxifen on estrogen and progesterone receptors in human breast cancer.

Authors:  N Waseda; Y Kato; H Imura; M Kurata
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

10.  Changes of steroid hormone receptor content by chemotherapy and/or endocrine therapy in advanced breast cancer.

Authors:  Y Nomura; H Tashiro; K Shinozuka
Journal:  Cancer       Date:  1985-02-01       Impact factor: 6.860

View more
  1 in total

1.  Growth dysregulation and p53 accumulation in human primary colorectal cancer.

Authors:  D S Watson; I Brotherick; B K Shenton; R G Wilson; F C Campbell
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.